News of Note—Inovio-AstraZeneca HPV study, Changsheng and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Investigators have started a phase 2 study at MD Anderson Cancer Center to test MedImmune’s MEDI0457, which AstraZeneca licensed from Inovio, in combination with Imfinzi in HPV-related cancers. Release

> Chinese stock regulators have started delisting Changchun Changsheng Life Sciences from the Shenzhen Stock Exchange over a major vaccine scandal. Xinhua article

> Batavia Biosciences will help the International AIDS Vaccine Initiative to develop a Lassa fever vaccine under a grant from the Coalition for Epidemic Preparedness Innovations. Release

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.